Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did not get the vaccine. View on euronews ...

LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...

Add Yahoo as a preferred source to see more of our stories on Google. With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

LIBERTY is a Phase 3, randomized, double-blind clinical trial to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and ...

The mass-produced COVID-19 vaccines built using the mRNA model – which were rapidly manufactured during the global pandemic – could also help the immune system recognise and attack cancer tumours, new ...

COVID-19 vaccines from Pfizer and Moderna should be pulled from circulation, a former Centers for Disease Control and Prevention official said in a new interview. “I really would like to see the mRNA ...

Holding meds does not enhance humoral immunogenicity and is associated with disease flares for patients with inflammatory arthritis.

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we ...